You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Feasibility, complications, morbidity, and mortality results at 6 months for aneurysm treatment with the Flow Re-Direction Endoluminal Device: report of SAFE study

Article Text

Article menu

Download PDFPDF

XML
Hemorrhagic Stroke
Original research
Feasibility, complications, morbidity, and mortality results at 6 months for aneurysm treatment with the Flow Re-Direction Endoluminal Device: report of SAFE study
  1. Laurent Pierot1,
  2. Laurent Spelle2,
  3. Jérôme Berge3,
  4. Anne-Christine Januel4,
  5. Denis Herbreteau5,
  6. Mohamed Aggour6,
  7. Michel Piotin7,
  8. Alessandra Biondi8,
  9. Xavier Barreau3,
  10. Charbel Mounayer9,
  11. Chrisanthi Papagiannaki10,
  12. Jean-Paul Lejeune11,
  13. Jean-Yves Gauvrit12,
  14. Vincent Costalat13
  1. 1 Department of Neuroradiology, Hôpital Maison-Blanche, Université Reims-Champagne-Ardenne, Reims, France
  2. 2 Department of Neuroradiology, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicetre, France
  3. 3 Department of Neuroradiology, CHU Pellegrin, Bordeaux, France
  4. 4 Department of Neuroradiology, CHU Toulouse, Toulouse, France
  5. 5 Department of Neuroradiology, Hôpital Bretonneau, Université François Rabelais, Tours, France
  6. 6 Department of Neuroradiology, CHU Saint-Etienne, Saint-Etienne, France
  7. 7 Department of Neuroradiology, Fondation Ophtalmologique A. de Rothschild, Paris, France
  8. 8 Department of Neuroradiology, Hôpital Jean-Minjoz, CHRU de Besançon, Besançon, France
  9. 9 Department of Neuroradiology, CHU Dupuytren, Limoges, France
  10. 10 Department of Neuroradiology, Hôpital Charles Nicolle, Université de Rouen, Rouen, France
  11. 11 Department of Neurosurgery, CHU Lille, Lille, France
  12. 12 Department of Neuroradiology, CHU Rennes, Rennes, France
  13. 13 Department of Neuroradiology, Hôpital Gui de Chauliac, Université de Montpellier, Montpellier, France
  1. Correspondence to Professor Laurent Pierot, Department of Neuroradiology, Hôpital Maison-Blanche, Reims cedex, 51092, France; lpierot{at}gmail.com

Abstract

Background and purpose Flow diverters are increasingly used for the treatment of intracranial aneurysms. Evaluation of the first devices available for clinical use showed high efficacy of this treatment although safety results were worse compared with coiling or balloon-assisted coiling. The Safety and Efficacy Analysis of FRED Embolic Device in Aneurysm Treatment (SAFE) trial is a single-arm, multicenter, prospective study conducted to precisely analyze the safety and efficacy of the FRED and FRED Jr devices.

Methods Unruptured and recanalized aneurysms located in the anterior circulation treated with FRED and FRED Jr were prospectively included. Adverse events were independently evaluated by a Clinical Event Committee with a vascular neurosurgeon and an interventional neuroradiologist. Primary safety outcome measures were morbidity and mortality rates at 6 months after treatment.

Results A total of 103 patients/aneurysms were included in 13 interventional neuroradiology (INR) centers. Aneurysm locations were supraclinoid internal carotid artery (ICA) in 71 (68.9%), cavernous ICA in 15 (14.6%), anterior cerebral artery or anterior communicating artery in nine (8.7%), and middle cerebral artery in eight (7.8%). Aneurysms were small (<10 mm) in 71 patients (68.9%). Treatment was successfully performed in 98/103 patients (95.1%). Thromboembolic (TE) complications occurred in 5/103 patients (4.9%), intraoperative rupture in 2/103 patients (1.9%), delayed aneurysm rupture in 1/103 patient (1.0%), and delayed hematoma occurred in 1/103 patient (1.0%). Six-months' mortality and morbidity rates were 1/102 (1.0%) and 2/102 (2.0%), respectively.

Conclusions Aneurysm treatment with the FRED device is safe with low mortality (1.0%) and morbidity (2.0%).

Clinical trial registration NCT02921698.

  • aneurysm

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/neurintsurg-2017-013559

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All authors have: provided a substantial contribution to the conception and design of the studies and/or the acquisition and/or the analysis of the data and/or the interpretation of the data. They have drafted the work or revised it for significant intellectual content and approved the final version of the manuscript. They agree to be accountable for all aspects of the work, including its accuracy and integrity.

    • Funding The SAFE study was funded by Microvention.

    • Competing interests LP is a consultant for Balt, Microvention, Neuravi, and Penumbra. LS is a consultant for Balt, Medtronic, Microvention, and Stryker. DH is consultant for Codman, Medtronic, Sequent ,and Stryker. MP is consultant for Balt, Medtronic, Microvention, and Stryker. AB is consultant for Balt, Medtronic, Microvention, Stryker, and Phenox. XB is consultant for Microvention, Sequent, and Stryker. VC is consultant for Microvention and Balt and receives educational grants from Medtronic and Stryker.

    • Ethics approval Reims IRB.

    • Provenance and peer review Not commissioned; externally peer reviewed.